Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05246397 · ClinicalTrials.gov registry record · Phase 4
Sugammadex Titration in Cardiac Surgery Patients
A Phase 4 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT05246397 is a Phase 4 study that has completed, run by University of Washington. The registered enrollment target is 100 participants.
The verdict
NCT05246397, a Phase 4 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Sugammadex is frequently used to reverse the effects of neuromuscular blocking drugs. The recommended doses are 2 mg/kg or 4 mg/kg depending upon the depth of neuromuscular blockade. Clinical studies and experience have suggested that smaller doses may be effective. The purpose of this observational study is to determine the minimal effective dose of sugammadex by administering 50 mg every 5 minutes until the train-of-four ratio is 0.9 in a cohort of cardiac surgery patients, and to determine the duration of action by measuring the train-of-four every hour for up to 6 hours following reversal.
Interventions
- DRUG Sugammadex administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2022-11-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05246397
The ClinicalTrials.gov registry entry for NCT05246397 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sugammadex administration is the first listed.
NCT05246397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05246397 about?
NCT05246397 is a clinical study titled "Sugammadex Titration in Cardiac Surgery Patients". Sugammadex is frequently used to reverse the effects of neuromuscular blocking drugs. The recommended doses are 2 mg/kg or 4 mg/kg depending upon the depth of neuromuscular blockade. Clinical studies and experience have suggested that smaller doses may be effective. The purpose of this observational...
What is the current status of trial NCT05246397?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2022-02-01. Estimated completion is 2022-11-10.
What interventions are being tested in trial NCT05246397?
The interventions under investigation include: Sugammadex administration (DRUG).
Who is sponsoring clinical trial NCT05246397?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.